Chemerin-9 (149-157) 是趋化因子样受体1 (CMKLR1)的有效激动剂。Chemerin-9 (149-157) 具有抗炎活性。Chemerin-9 (149-157) 刺激 Akt 和 ERK 的磷酸化以及活性氧的产生。Chemerin-9 (149-157) 改善 Aβ1-42诱导的记忆障碍。Chemerin-9 (149-157) 调节免疫反应、脂肪细胞分化和糖代谢。
| 生物活性 | Chemerin-9 (149-157) is a potent agonist ofchemokine-like receptor 1 (CMKLR1). Chemerin-9 (149-157) has anti-inflammatory activity. Chemerin-9 (149-157) stimulates phosphorylation ofAktandERKas well as ROS production. Chemerin-9 (149-157) ameliorates Aβ1-42-induced memory impairmen. Chemerin-9 (149-157) regulates immune responses, adipocyte differentiation, and glucose metabolism[1][2][3][4]. |
体外研究
(In Vitro) | Chemerin-9 (149-157) (0.1 nM; 24 h; cardiac fibroblasts) stimulates migration in cardiac fibroblasts and stimulates phosphorylation of Akt and ERK as well as ROS production[4].
Western Blot Analysis[4] | Cell Line: | Cardiac fibroblasts | | Concentration: | 0.1 nM | | Incubation Time: | 24 hours | | Result: | Stimulated phosphorylation of Akt and ERK. |
|
体内研究
(In Vivo) | Chemerin-9 (149-157) (0.2 mg/kg; i.p.; daily, for 42 days) alleviates glucose intolerance and IR in PDM mice[1].
Chemerin-9 (149-157) (7.7 μg /kg; i.h.; daily, for 28 days) has anti-inflammatory and anti-angiogenic effects in ApoE-/-mice and protects the abdominal aorta from MMP damage[2].
Chemerin-9 (149-157) (8 μg/kg; ICV; daily; for 14 d; male Kunming mice) ameliorates Aβ1-42-induced memory impairment[3].
| Animal Model: | PDM mice[1] | | Dosage: | 0.2 mg/kg | | Administration: | Intraperitoneal injection; daily, for 42 days | | Result: | Increased expression of chemerin, GLUT2, and PDX1, which led to the alleviation of glucose intolerance and IR in PDM model mice. |
| Animal Model: | ApoE-/-mice[2] | | Dosage: | 7.7 μg /kg | | Administration: | Subcutaneous injection; daily, for 28 days | | Result: | Suppressed the enlargement of abdominal aorta and reversed the SMC loss. |
| Animal Model: | ApoE-/-mice[2] | | Dosage: | 7.7 μg /kg | | Administration: | Subcutaneous injection; daily, for 28 days | | Result: | Down-regulated MMP2 and MMP-9 expression and decreased the levels of chemerin and CMKLR1. |
| Animal Model: | Male Kunming mice[3] | | Dosage: | 8 μg/kg | | Administration: | Intracerebroventrical injection; daily; for 14 days | | Result: | Increased in the levels of pro-inflammatory cytokines such as interleukin-1β (IL-1β), tumor necrosis factor (TNF-α) and interleukin-6 (IL-6) in the hippocampus. |
|
| 分子量 | |
| Formula | |
| CAS 号 | |
| Sequence Shortening | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Solvent & Solubility | In Vitro: H2O Peptide Solubility and Storage Guidelines: 1. Calculate the length of the peptide. 2. Calculate the overall charge of the entire peptide according to the following table: | | Contents | Assign value | | Acidic amino acid | Asp (D), Glu (E), and the C-terminal -COOH. | -1 | | Basic amino acid | Arg (R), Lys (K), His (H), and the N-terminal -NH2 | +1 | | Neutral amino acid | Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) | 0 |
3. Recommended solution: | Overall charge of peptide | Details | | Negative (<0) | 1. Try to dissolve the peptide in water first.
2. If water fails, add NH4OH (<50 μL).
3. If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide. | | Positive (>0) | 1. Try to dissolve the peptide in water first.
2. If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3. If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO. | | Zero (=0) | 1. Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2. For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration. |
|
m.cnreagent.com